PYXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PYXS is not a good buy right now. The stock is in a bearish trend (SMA200 > SMA20 > SMA5) and just sold off to ~$1.455, sitting below the key pivot (1.697) and under the first support (1.495). With no Intellectia buy signals today and short-term pattern odds skewing slightly negative over the next day/week, the higher-probability move is continued chop/down before a sustainable reversal. For an impatient investor, I would avoid initiating a new long here and instead stay on the sidelines/hold until price reclaims at least the 1.70 pivot area with improving momentum.
Price/Trend: PYXS is down -6.73% to 1.455, in a clearly bearish structure with moving averages stacked negatively (SMA200 > SMA20 > SMA5), signaling an established downtrend. Momentum: RSI(6) ~33.7 is weak (near oversold territory), which can support short bounces, but it is not a strong buy signal by itself. MACD histogram is positive (0.0606) but positively contracting, which often aligns with weakening upside momentum during a broader downtrend. Levels: Pivot 1.697 is the key reclaim level for bulls. Immediate levels: S1 1.495 (already below), S2 1.37 (next downside magnet). Upside resistance sits at R1 1.90 and R2 2.025, but the chart first needs to regain 1.70 to improve odds. Pattern-based short-horizon outlook: Similar-pattern stats indicate ~60% chance of -1.54% next day and -0.62% next week, with a modest +2.41% expectation next month—suggesting near-term pressure despite potential for a later bounce.
Intellectia Proprietary Trading Signals
Analyst support remains broadly positive (multiple Buy/Overweight/Outperform ratings) and targets remain far above the current price, which can help sentiment.
Clinical narrative: MICVO data has been described as showing efficacy potential and combinatorial synergy opportunities by at least one major analyst.
Options positioning is strongly call-leaning, which can occasionally amplify upside moves if shares start to reverse.
Technical trend is bearish (negative MA stack) and price is below the pivot and below S1 support, increasing odds of a drift toward S2 (~1.37).
Clinical update concerns noted by RBC: high adverse event/discontinuation rate and a smaller-than-expected update contributed to complexity/uncertainty.
No fresh news/catalysts in the most recent week to act as an immediate driver for an impatient, near-term entry.
Short-term pattern probabilities lean slightly negative for the next day/week.
Latest quarter: 2025/Q3. Revenue was 0 (no commercial revenue), consistent with a development-stage biotech profile. Net income improved modestly YoY to -$22.003M (up ~3.77% YoY), indicating slightly reduced losses but still meaningful cash burn. EPS was -$0.35. Overall, the quarter shows incremental improvement in losses but not a fundamental growth inflection (no revenue ramp).
Recent analyst trend is net-positive on ratings (Buy/Overweight/Outperform maintained) with mixed price-target actions:
